Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rallybio (RLYB) Non Operating Investment Income (2023 - 2025)

Rallybio's Non Operating Investment Income history spans 3 years, with the latest figure at $7000.0 for Q3 2025.

  • For Q3 2025, Non Operating Investment Income fell 97.08% year-over-year to $7000.0; the TTM value through Sep 2025 reached -$145000.0, down 138.46%, while the annual FY2024 figure was $53000.0, 76.86% down from the prior year.
  • Non Operating Investment Income for Q3 2025 was $7000.0 at Rallybio, up from -$30000.0 in the prior quarter.
  • Across five years, Non Operating Investment Income topped out at $240000.0 in Q3 2024 and bottomed at -$211000.0 in Q2 2023.
  • The 3-year median for Non Operating Investment Income is -$7000.0 (2025), against an average of $23800.0.
  • The largest YoY upside for Non Operating Investment Income was 275.0% in 2024 against a maximum downside of 156.21% in 2024.
  • A 3-year view of Non Operating Investment Income shows it stood at $223000.0 in 2023, then crashed by 145.29% to -$101000.0 in 2024, then surged by 106.93% to $7000.0 in 2025.
  • Per Business Quant, the three most recent readings for RLYB's Non Operating Investment Income are $7000.0 (Q3 2025), -$30000.0 (Q2 2025), and -$21000.0 (Q1 2025).